Needham reiterates Buy on NeoGenomics, keeps $22 target

Needham maintained their Buy rating on NeoGenomics's stock with a price target of $22.00, implying an upside of 15.0% from the Oct 5 close of $19.13. The firm noted strong revenue growth, with 3Q26 revenue of $2...